From MicrobeWiki, the student-edited microbiology resource
A Microbial Biorealm page on the genus Histoplasma capsulatum
Higher order taxa
Cellular Organisms; Eukaryota (Superkingdom); Fungi (Kingdom); Dikarya (Subkingdom); Ascomycota (Phylum); Pezizomycotina (Subphylum); Eurotiomycetes (Class); Eurotiomycetidae (Subclass); Onygenales (Order); Ajellomycetaceae (Family); Ajellomyces (Genus) 
Species: Ajellomyces capsulata
Anamorph (an asexal reproductive stage): Histoplasma capsulatum 
Description and significance
Histoplasma capsulatum is a fungal pathogen that can result in a wide range of clinical presentations, from asymptomatic through fatal infection. It usually causes lung disease called Histoplamosis or Darling’s disease. It is called Darling’s disease because it was found by Samuel Darling in histopathologic specimens about a century ago. [2, 4]
Histoplasma capsulatum is a biologically interesting inhabitant of soil and mammalian hosts, a clinically significant cause of respiratory and systemic infection, and an excellent fungal model of dimorphic cell development and facultative intracellular pathogenesis.  H. capsulatum is unique in its dimorphism. Dimorphism allows H. capsulatum to infect mammals by going through three significant development stages depends on the temperature shift from 25 °C to 37 °C. [1, 12] In the moist soil that is rich in bird or bat guano at temperature about 25 °C, H. capsulatum exists in a filamentous mycelia form.  However, when humans inhale H. capsulatum into their respiratory tracks, in order to replicate its DNA in the host at 37C, the pathogen has to be able to convert its tissue from one form to another. In this case, H. Capsulatum changed from fungi to yeast when it’s growing in the human bodies. [5, 16] H. capsulatum is thought to cause approximately 500,000 respiratory infections a year in the central river valleys in the Midwestern and south central United States. [2, 7, 11]
Histoplasma capsulatum reproduces when it is in the mold form of the fungus and is heterothallic. H. capsulatum is the anamorphic classification, while the teleomorph or perfect form is known as Ajellomyces capsulatus. Many approaches have been used to differentiate H. capsulatum strains. Three variants have been described based on host predilection, clinical presentation, geographic distribution, or serology: variant duboisii in Africa, variant farciminosum in horses, and variant capsulatum for the mijority isolates. [4, 5] The structure of H. capsulatum has not yet been studied with detail. There have been studies that focused on the polysaccharides composition of the cell walls.  The genome of H. capsulatum has also not yet been totally sequenced; however, certain strains of DNA have been studied. For examples, the G217B, G186A, and the Downs strain.  Many of the research centers are currently focusing on constructing the genome of H. capsulatum, such as University of Washington School of Medicine, and the Broad Institute. [8, 13] It will be useful to sequence the genome of H. capsulatum, because it can help answering many biological questions that scientists have. For example, the capacity to undergo the morphologic transition to the yeast phase, the different genes code for different functions necessary for survival, and the phase specific genes regulation. 
For Histoplasma capsulatum, functional genomic analysis preceded a genome sequence, demonstrating that genomics can be applied to organisms that have not been sequenced. [5, 9] However, some strains of DNA of H. capsulatum have been sequenced and studied. Most of the molecular studies of H. capsulatum were done with G217B, G186A, and the Downs strain. The G217B and the Downs strain are North American clinical isolates and G186A is a clinical isolate from Panama. [4, 5]
Originally H. capsulatum strains were classified into two types based on the polysaccharide composition of the cell walls. G217B belongs to type I, and it lacks α-(1,3)-glucan in its cell wall, while G186A belongs to type II because it has large amounts of α-(1,3)-glucan in its cell wall. This was interesting because for G186A variants that lack α-(1,3)-glucan are avirulent whereas G217B contains no α-(1,3)-glucan but is fully virulent. Therefore, the relationship between α-(1,3)-glucan and the H. capsulatum pathogenesis is relatable. [5, 19]
Downs strain unlike G217B and G186A strains; it is avirulent in standard animal models. However, it is shown that Downs strain is a temperature-sensitive strain that has to do with patients who are probably immunocompromised and have Histoplasmosis. Studies of H. capsulatum Downs strain were done on AIDS patients and it showed close relationship between the patients’ immune system and the Downs strain. [1,5] Downs strain also plays a role in the sensitivity to the temperature change when H. capsulatum changes its forms from mycelium to yeast. It is shown that when the environment of the temperature is changing, H. capsulatum activates its “heat shock” (hs) genes during the induction of the yeast phase. These heat shock genes help H. capsulatum adapting new environment and allowing it to invade a human host. Downs strain heat shock protein peaked at 34 °C, and in strain G217B, the response was highest at 37 °C. [1, 9, 12] The comparison of the different strains of H. capsulatum genes aids the understanding the biology of H. capsulatum, perhaps future genome projects on H. capsulatum will be done and be able to help us increase our knowledge towards H. capsulatum.
Different nutrients and compounds are required for the growth of Histoplasma capsultum in different stages of its development. The nutritional requirements for the mycelia stage are simple; the organism can grow in a 25 °C with glucose as its sole source of carbon and ammonia as its source of nitrogen. During the yeast phase, H. capsulatum requires more complex compounds and a higher temperature environment. For the yeast phase, it first needs sulfhydryl-containing compounds for initiation of yeast development and cysteine or cystine along with certain growth factors such as biotin, thiamine, or thiotic acid in order to maintain the morphology. [1, 10] Cysteine plays an important role in the morphogenesis of H. capsulatum. It allows the cell to perform respiration for both phases and during the transition. There are two terminal oxidase pathways for H. capsulatum: the cytochrome system which is blocked by cyanide and antimycin; the other, an unidentified alternative oxidase that is specifically blocked by salicylhydroxamic (SHAM). 
Another nutrient that is important for the growth of Histoplasma capsulatum is Iron. Iron is essential in redox reaction related to its existence in reduced Fe2+ and oxidized Fe3+ states. For a pathogen to be successful, it must have countermechanisms for acquiring iron in the host microenvironment which it exists due to the limited amount of free soluble iron in an animal. There are a few approaches for the iron acquisition of H. capsulatum that have been studied. These strategies are: siderophores, acidic pH, reductive activities, and receptors for host iron-binding compounds. None of these approaches is unique because they can also be seen in other organisms; however, the coexistence of such plethora in a single microbe is distinctive. [4, 9]
Histoplasma capsulatum is widely distributed throughout the sutropial and tropical zones of the world. It is the etiologic agent of the most common respiratory fungal infection affecting humans, especially those who have weak immune systems such as AIDS patients. In n America, H. capsulatum is particularly associated with the Mississippi and Ohio River valleys. [2, 4, 5] Throughout the development of H. capsulatum, three distinct stages depending on the temperature shift between 25°C to 37°C have been identified. 
Stage 1 usually taken place in the moist rich soil. In the soil, H. capsulatum mycelia give rise to two types of spores: tuberculate macroconidia (8 to 14 µm in diameter) and microconidia (2 to 5 µm in diameter). [1, 3, 4, 5] Although it is not yet been indentified, it is likely that microconidia are the major infectious due to their small size, making them readily aerosolization and able to penetrate to the small airways of mammalian lungs by inhalation.  Stage I begins immediately after the temperature shift. During this stage, the respiration rate of mycelia and the intracellular cystein concentration both decrease. It also shows a partial uncoupling of oxidative phosphorylation. This stage lasts between twenty-four and forty hours before H. capsulatum enters stage II. 
Stage II takes place in an environment of 37 °C. Under this condition, Histoplasma capsulatum exists as a uninucleate oval budding yeast, 2 to 4 µm in diameter, with a narrow bud neck. Once inhaled, conidia could be phagocytosed and then undergo the dimorphic transition inside host cell. A simple temperature change is sufficient to cause the transition from mycelia to yeast although some other environmental stimuli are involved and may override the thermal signal.  In stage II, the respiration rate is reduced which lasts 4 to 6 days and it will then enter stage III.  Addition of cysteine or other sulfhydryl-containing compounds during stage II accelerates the mycelium-to-yeast transition. Cystein has at least two functions in the phase transition in H. capsulatum: 1. it is required in stage II for mycelia cells to complete the transition to yeast; and 2. Yeast phase cells contains a cysteine oxidase and yeasts have a nutritional need for cysteine that can not be satisfied by other compounds.  In stage III, there is a gradual recovery of cellular respiration to the level characteristics of yeast with a related increase in the concentration of cysteine and other amino acids.
Histoplasma capsulatum also modulates the pH value of its environment, maintaining a more neutral condition. Intracellular compartments containing zymosan particles or dead H. capsulatum yeast were at a considerably lower pH than those containing viable H. capsulatum yeasts. The detailed mechanism of the pH modulation has not yet been studied, but it is thought that the modulation helps the survival of H. capsulatum.  The transition from stage to stage is unique for Histoplasma capsulatum. As a pathogen, the fungus must face challenges that may not be related strictly to the process of dimorphism such as higher temperature, different oxidation-reduction potentials, and a hostile host environment. 
Histoplasma capsulatum causes histoplasmosis or Darling’s disease in humans, the degree of its severity depends on individual’s immune system, the degree of exposure and dosage of organisms since more infectious are asymptomatic or subclinical when they occur.  H. capsulatum occurs by the respiratory route via inhalation of particles from environment. Conidia, spores and other infectious propagules are inhaled and lodge on the mucous membranes of the respiratory tree or in the alveoli of the lungs, where they encounter macrophages and are phagocytosed.  Also, H. capsulatum is able to reactive in the host when the host becomes immunosuppressive, such as immunodeficiency or cancer.  The frequency of being infected by histoplasmosis is approximately 250,000 individuals annually in the US and the clinical symptoms occur in less than 5% of the population. [1, 2] Internationally, H. capsulatum can be found in river valleys between latitudes 45° north and 30° south in North and Central America. There also been cases of patients diagnosed with histoplasmosis in some Asia countries, such as Taiwan.  Although histoplasmosis can affect individuals of any age, those in extreme age ranges are more prone to developing infection as a result of immature or deteriorated immune defenses. [1, 2, 7]
The symptoms of hitoplasmosis are like the ones for flu. Majority of the infected patients show no ill effects. The acute respiratory disease is the one major symptom. The patient may feel fever, chest pains, a general ill feeling, and a dry cough. Distinct patterns may be seen on a chest x-ray. Chronic lung disease resembles tuberculosis and can worsen over months or years. The disseminated form is fatal unless treated. If symptoms occur, they will start within 3 to 17 days after exposure; the average is 10 days. [2, 7] histoplasmosis can also cause a serious eye disease called ocular histoplasmosis syndrome (OHS), a leading cause of vision loss in Americans ages 20 to 40. Scientists believe that H. capsulatum spores spread from the lungs to the eyes; however, the detailed mechanism of how the fungus spread has not yet been traced. 
An interesting study has done comparing H. capsulatum to Mycobacterium tuberculosis and tuberculosis based on several aspects of biology, infection, and pathogenesis. Here are the similarities: 1. they are both facultative intracellular pathogens of macrophages that must modulate or survive the harsh environment in the antimicrobial hot cells, 2. infection by both organisms occurs by the respiratory route via inhalation of particles from the environment, 3. both establish an initial pulmonary infection but can readily disseminate throughout the mononuclear phagocytic system, e.g., liver, spleen, and bone marrow, 4. both can be detected by skin testing with microbial antigens reflecting delayed-type hypersensitivity as a marker of past exposure and finally, 5. reactivation disease can occur if the host becomes immunocompromise. A good distinction between M. tuberculosis and H. capsulatum is that HC is not contagious except in very rare cases of transmission via transplantation of infected organs, a feature shared with the majority of fungal diseases. [4, 9]
The best way to reduce a person’s exposure is to avoid areas that may harbor the fungus, such as accumulations of bird or bat droppings. Centers for Disease Control and Prevention (CDC) also provides a document called “NIOSH/NCID Document Histoplasmosis: Protecting Workers at Risk”; it provides information on work practices and personal protective equipment that will reduce the risk of infection. 
The biology of Histoplasma capsulatum is still not fully understood, such as the detail structure and mechanism of each transition stage, the regulation of its developments, and the genome sequencing. Most of the current research focuses on the genomics that will contribute to the identification of genes and regulatory circuits that all H. capsulatum to sense, response to, and manipulate its environment, whether in soil or a mammalian host. In addition, acomparative genomic analysis of H. capsulatum and other fungi will contribute to our understanding of the diversity of the fungal kingdom. 
There have been many outstanding research projects done at Washington University, School of Medicine. One of the leaders of the research team, George S. Kobayashi, Ph.D., is interested in elucidating the mechanisms that trigger and control the dimorphism of H. capsulatum. He and his team are interested in the gene expression during the temperature-induced transition because it is important medically for eukaryotic pathogens. Also, they are interested in the host-parasite interaction of H. capsulatum yeast and the activities manifested by inhibition of macrophage respiratory burst activity. [12, 13]
Histoplasma capsulatum is also being studied for its pathogenesis. Untreated histoplasmosis is life threatening especially in immunosuppressed patients. A recent paper published explained a new method to help diagnose histoplamosis faster. The study was done in French Guiana, South America, in the mycology laboratory of Cayenne hospital. Instead of the lengthy process of culture samples for histoplasmosis, the research team used polymerase chain reaction (PCR) method. They tested it on 40 samples from patients with suspected disseminated histoplasmosis and the results were positive with PCR method which is consistent with the results from culturing method. This method also showed high specificity on other fungi. Although culture remains necessary, the new PCR method allows treating patients more rapidly and it offers great prospects on a clinical point of view. 
Another research has done on the α-(1,3)-glucan of the Histoplasma capsulatum call wall. The study was done from Bill Goldman’s laboratory. There, Chad Rappleye and colleagues studied the innate immune response to H. capsulatum from both the host and fungal perspective. They investigated the role for α-(1,3)-glucan, chitin, and β-glucans, which are the polysaccharide components found in the H. capsulatum cell wall. For 30 years, the relationship between α-(1,3)-glucan and its virulence has not yet been cleared. Using immunofluoresence microscopy, Rappleye et al. found that the H. capsulatum cell wall has a layered structure, with the α-(1,3)-glucan comprising the outermost layer, confirming earlier biochemical analyses. 
1. Bossche, Hugo, Frank Odds, and David Kerridge. Dimorphic Fungi in Biology and Medicine. 1st ed. New York and London: Plenum Press, 1993
2. Chang, Ryan. "Histoplasmosis." 19 Sep 2005. emedicine. 25 Aug 2007 <http://www.emedicine.com/MED/topic1021.htm>.
3. Hayward, Chris A. "Microorganisms." Encyclopedia of Life Sciences 20062006 1-13. <http://www.mrw.interscience.wiley.com/emrw/9780470015902/els/article/a0000460/current/pdf>.
4. Heitman, Joseph, Scott G. Filler, Aaron P. Mitchell, and John E. Edwards, Jr.Molecular Principles of Fungal Pathogenesis. 1st ed. New York: ASM Press, 2006. (Heitman et al. 321-331)
5. Heitman, Joseph, Scott G. Filler, Aaron P. Mitchell, and John E. Edwards, Jr.Molecular Principles of Fungal Pathogenesis. 1st ed. New York: ASM Press, 2006. (Heitman et al. 611-626)
6. "Histoplasmosis." Histoplasmosis Resource Guide. Mar 2007. National Eye Institute. 25 Aug 2007 <http://www.nei.nih.gov/health/histoplasmosis/index.asp>.
7. "Histoplasmosis." Centers for Disease Control and Prevention. 12 Oct 2005. Centers for Disease Control and Prevention. 25 Aug 2007 <http://www.cdc.gov/ncidod/dbmd/diseaseinfo/histoplasmosis_g.htm>.
8. "Histoplasma capsulatum Database." BROAD INSTITUTE. 20 Aug 2007. BROAD INSTITUTE. 20 Aug 2007 <http://www.broad.mit.edu/annotation/genome/histoplasma_capsulatum/Home.html>.
9. Hwang, Lena, Davina Hocking-Murray, Adam K. Bahrami, Margareta Andersson, and Jasper Rine. "Identifying Phase-specific Genes in the Fungal Pathogen Histoplasma capsulatum Using Genomic Shotgun Microarray." Molecular Biology of the Cell June 2003 2314-2326. .
10. Johnson, Clayton, Jonathan T. Prigge, Aaron D. Warren, and Joan E. McEwen. "Characterization of an alternative oxidase activity of Histoplasma Capsulatum." Yeast 2003 381-388. .
11. Kendrick, Bryce. "Fungi: Ecological Importane and Impact on Humans." Encyclopedia of Life Sciences 20012001 1-5. <http://www.mrw.interscience.wiley.com/emrw/9780470015902/els/article/a0000369/current/pdf>.
12. Kobayashi, George S. "Mycoses." Encyclopedia of Life Sciences 20012001 1-6. <http://www.mrw.interscience.wiley.com/emrw/9780470015902/els/article/a0000371/current/pdf>.
13. Kobayashi, George S.. "Molecular Basis of Adaptation in Histoplasma capsulatum ." Washington University School of Medicine. 25 Aug 2007 <http://research.medicine.wustl.edu/OCFR/Research.nsf/Abstracts/64ABA9996B650C50862567ED00029E69?OpenDocument&VW=Infectious+Diseases>.
14. Lai, Chung-Hsu, Chun-Kai Huang, Chuen Chin, Ya-Ting Yang, and Hsiu-Fang Lin. "Indigenous Case of Disseminated Histoplasmosis, Taiwan." Emerging Infectious Diseases Jan 2007 127-129. .
15. Maubon, Daniele, Stephane Simon, and Christine Aznar. "Histoplasmosis diagnosis using a polymerase chain reaction method. Application on human samples in French Guiana, South America." 04 Aug 2007
16. Mitchell, Thomas G. "Fungal Pathogens of Human." Encyclopedia of Life Science 20022002 1-15. <http://www.mrw.interscience.wiley.com/emrw/9780470015902/els/article/a0000359/current/pdf?hd=All%2Chistoplasma&hd=All%2Ccapsulatum>.
17. National Center for Biotechnology Information (NCBI) Taxonomy Browser. Taxonomy ID:5037
18. Nittler, M.Paige, Davina Hocking-Murray, Catherine K. Foo, and Anita Sil. "Identification of Histoplasma capsulatum Transcripts Induced in Response to Reactive Nitrogen Species." Molecular Biology of the Cell Oct 2005 4792-4813. .
19. Rappleye, C. A., Eissenberg, L. G. & Goldman, W. E. Histoplasma capsulatum (1,3)-glucan blocks innate immune recognition by the -glucan receptor. Proc. Natl Acad. Sci. USA 23, 1366–1370 (2007)
Image Source: 20. Scientific Institute of Public Health, Belgium, http://www.iph.fgov.be/
Edited by Shen-Yin (Mandy) Hung of Rachel Larsen
Edited by KLB